Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 0: clinchem.2004.044511v1, 2005; 10.1373/clinchem.2004.044511
This Article
Right arrow Full Text (PDF)
Right arrow Data Supplements
Right arrow All Versions of this Article:
clinchem.2004.044511v1
51/4/729    most recent
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Okosieme, O. E.
Right arrow Articles by Lazarus, J. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Okosieme, O. E.
Right arrow Articles by Lazarus, J. H.

Received on October 26, 2004
Accepted on January 18, 2005

Endocrinology and Metabolism

Thyroglobulin Antibodies in Serum of Patients with Differentiated Thyroid Cancer: Relationship between Epitope Specificities and Thyroglobulin Recovery

Onyebuchi E. Okosieme 1*, Carol Evans 2, Laura Moss 3, Arthur B. Parkes 1, L. Kuvera D.E. Premawardhana 1, John H. Lazarus 1

1 Centre for Endocrine and Diabetes Science, School of Medicine, Cardiff University, Cardiff, UK
2 Department of Medical Biochemistry, University Hospital of Wales NHS Trust, Cardiff, UK
3 Oncology Department, Velindre Hospital, Cardiff, UK

* To whom correspondence should be addressed. E-mail: okosiemeoe{at}cf.ac.uk.

Background: Serum antibodies against thyroglobulin (TgAbs) are common in patients with differentiated thyroid cancer (DTC) and can interfere in thyroglobulin (Tg) assays. We identified the epitopes on Tg recognized by TgAb-positive sera from patients with DTC and examined the association between epitope specificity patterns and Tg recovery.

Methods: We tested 50 DTC sera for Tg epitope specificity, TgAbs, and Tg recovery. Epitope recognition was determined by use of a panel of 10 well-characterized Tg monoclonal antibodies directed against 6 Tg antigenic clusters (I-VI) in competitive reactions with test sera. Tg was measured by the Thyroglobuline IRMA (CIS bio international). Recovery of added Tg (TgREC) was determined by an in-house assay.

Results: Epitope recognition was restricted to immunodominant clusters in 58% of patients, whereas the rest were either broadly heterogeneous (16%) or nonreactive (26%). Median Tg recovery did not differ between sera with restricted and unrestricted specificities (68.7% vs 80.5%; P >0.05). TgREC was inversely correlated with the total number of epitopes recognized by sera (r = -0.66; P <0.001).

Conclusion: TgAbs with both restricted and broad specificities are present in patients with DTC. TgAb interference is related to the number of epitopes recognized by sera rather than the pattern of epitope recognition.




The following articles in journals at HighWire Press have cited this article:


Home page
J. Clin. Endocrinol. Metab.Home page
C. A. Spencer, L. M. Bergoglio, M. Kazarosyan, S. Fatemi, and J. S. LoPresti
Clinical Impact of Thyroglobulin (Tg) and Tg Autoantibody Method Differences on the Management of Patients with Differentiated Thyroid Carcinomas
J. Clin. Endocrinol. Metab., October 1, 2005; 90(10): 5566 - 5575.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2005 by the American Association for Clinical Chemistry.